NCT00659581已完成不适用
Special Survey (Survey on Cerebrovascular and Cardiovascular Events Under Long-term Use) of Micardis Tablets (Telmisartan)
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 21,471
- 主要终点
- Number of Patients With Cerebrovascular(CeV) and Cardiovascular (CaV) Events
研究概览
简要总结
The primary objective of this post marketing survey is to prospectively investigate patients with hypertension treated with Micardis Tablets (hereinafter "this drug") in routine clinical settings for 3 years in order to determine the following:
- Adverse events and adverse drug reactions under long-term use
- Blood pressure measurements during the survey period
- Determination of the incidence of cerebrovascular and cardiovascular events under use of this drug in routine clinical settings
- Patient's lifestyle and background factors that are considered to affect the occurrence of cerebrovascular and cardiovascular events
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Patients with hypertension
干预措施: Telmisartan (Drug)
结局指标
主要结局
Number of Patients With Cerebrovascular(CeV) and Cardiovascular (CaV) Events
时间窗: 3 years after initiation of treatment
次要结局
- Change From Baseline in Systolic Blood Pressure at 12 Months(initiation and 12 months)
- Change From Baseline in Systolic Blood Pressure at 36 Months(initiation and 36 months)
- Change From Baseline in Diastolic Blood Pressure at 36 Months(initiation and 36 months)
- Change From Baseline in Diastolic Blood Pressure at 12 Months(initiation and 12 months)
- Change From Baseline in Diastolic Blood Pressure at 6 Months(initiation and 6 months)
- Change From Baseline in Systolic Blood Pressure at 24 Months(initiation and 24 months)
- Change From Baseline in Diastolic Blood Pressure at 24 Months(initiation and 24 months)
- Change From Baseline in Systolic Blood Pressure at 6 Months(initiation and 6 months)
研究者
相似试验
已完成
不适用
Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic DrugEpilepsies, PartialNCT01098162UCB Pharma GmbH576
已完成
不适用
Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.HER2-negative Breast CancerBreast CancerNCT02371174Eisai Co., Ltd.651
已完成
不适用
Pioglitazone Special Drug Use Surveillance "Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus"Type 2 Diabetes MellitusNCT02002975Takeda18,223
已完成
不适用
Detection and Neurological Impact of Cerebrovascular Events in Cardiac Surgery PatientsSilent StrokeCognitive DeclineNCT04241289Population Health Research Institute66
Unknown
不适用
Integrated Assessment of Cervicocerebral Vessels to Improve the Brain Injury for CAGB Patients (IACV Study)Coronary DiseaseCoronary Artery BypassStrokes ThromboticNCT06275139China National Center for Cardiovascular Diseases348